BBIO — BridgeBio Pharma Share News
0.000.00%
Last trade - 00:00- $13.12bn
- $15.77bn
- $502.08m
BridgeBio Q4 revenue jumps on Attruby sales
Brief: BridgeBio Pharma Q4 Net Income USD -194.635 Million
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
U.S. RESEARCH ROUNDUP- Applied Materials, Humana, Gilead
U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln National
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Iron Mountain, BridgeBio, Old Dominion,
BridgeBio rises after study shows drug improving growth in children with dwarfism
Brief: Bridgebio Reports Positive Phase 3 Topline Results For Oral Infigratinib
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study
Brief: Bridgebio Pharma Inc Issues $632.5 Million Convertible Senior Notes Due 2033
U.S. STOCKS ON THE MOVE -Analog Devices, BridgeBio, TransDigm
BridgeBio rises after $550 mln convertible debt offering
BridgeBio dips after unveiling $550 mln convertible bond deal
Brief: Bridgebio Continues Long Term Debt Management Strategy And Announces Proposed Offering Of Convertible Senior Notes
Brief: BridgeBio Pharma Reports Attruby Product Revenue $146 Mln In Q4
Brief: BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Alphabet, Boeing, KLA
BridgeBio Q3 revenue jumps to $120.7 mln